Form 4: Cue Biopharma's Chief Medical Officer Acquires 260,000 Stock Options
SEC Form 4 Filing
Matteo Levisetti, Chief Medical Officer of Cue Biopharma, acquired 260,000 stock options on March 6, 2024, exercisable in installments starting September 6, 2024.
Summary
- On March 6, 2024, Matteo Levisetti, the Chief Medical Officer of Cue Biopharma, Inc., acquired 260,000 stock options.
- The exercise price of these options is $1.94 per share.
- The options become exercisable in eight equal semi-annual installments beginning on September 6, 2024.
- The expiration date for these stock options is March 5, 2034.
- Following the transaction, Mr. Levisetti directly owns 260,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options to the CMO suggests confidence in the company's future, but it's a routine transaction.
Positives
- The acquisition of stock options by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future prospects.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a long-term commitment from the executive.
Industry Context
Stock option grants are a common practice in the biopharmaceutical industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to align executive interests with shareholder value.
- The vesting schedule of semi-annual installments is a fairly standard approach to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view this as a positive sign, indicating that the Chief Medical Officer is incentivized to contribute to the company's long-term success.
- Employees may see this as a sign of stability and confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of transaction: Matteo Levisetti acquired 260,000 stock options. |
| 09/06/2024 | First vesting date: Stock options become exercisable in eight equal semi-annual installments beginning on this date. |
| 03/05/2034 | Expiration date of the stock options. |
| 03/08/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.